Outcome of Board Meeting held on 13th February, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250 and 5.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported zero revenue from operations across all periods, with total income coming entirely from 'other income' of ₹6.45 lakh in Q3 (vs ₹0.30 lakh in Q3FY25) and ₹112.19 lakh for 9MFY26 (vs ₹57.40 lakh in 9MFY25). Profit after tax for Q3 was ₹6.10 lakh compared to a loss of ₹6.20 lakh in the year-ago quarter, while 9MFY26 PAT surged to ₹80.22 lakh (incl. OCI) from ₹16.77 lakh last year. The statutory auditor's review report flags multiple serious concerns in an Emphasis of Matter section: inability to verify the end-use of funds raised through preferential allotment, uncertainty around related-party transactions and arm's-length pricing, non-compliance with GST and Income-tax filing/deposit requirements that could materially impact the accounts, and absence of independent confirmations for debtors, creditors, investments, and loans/advances.
Significant red flags raised by the auditor—including questionable use of preferential allotment proceeds, potential related-party concerns, and statutory non-compliance—undermine the reliability of the numbers despite the strong profit growth. The auditor has effectively disclaimed an opinion on the results, which is a serious governance concern and could weigh on the stock and investor confidence.